« Zurück
Startseite /
Plerixafor octahydrochloride

Plerixafor octahydrochloride

215,00 €

Zzgl. MwSt.

ArtNr	HY-50912-50mg
Hersteller	MedChem Express
CAS-Nr.	155148-31-5
Menge	50 mg
Kategorie	Neuroscience Neural Lineage Markers Neuroinflammation Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	98.0
Formula	C28H62Cl8N8
Citations	Adv Funct Mater. 2020, 2000309. Anticancer Drugs. 2017 Oct;28(9):935-942. Brain Behav Immun. 2017 Jan;59:322-332. Mol Ther-Nucl Acids. 2023 Mar 9. Oncogene. 2022 Oct;41(41):4633-4644. Oxid Med Cell Longev. 2021 Aug 2;2021:9993240. Patent. US20190133998Al Pharmaceutics. 2021 Mar 24;13(4):439. Ruprecht-Karls-University Heidelberg. 2023 Aug 3. ACS Infect Dis. 2023 Oct 5. Andrology. 2022 Sep 16. Bioact Mater. 2021 Jan 7;6(7):2039-2057. Biochem Biophys Res Commun. 2021 Jan 1;534:337-342. Biomed Pharmacother. 2020, 110610. BMC Complement Altern Med. 2018 Dec 12;18(1):330. Br J Haematol. 2022 Dec 19. Cancer Lett. 2022 Oct 7;551:215944. Cell Death Dis. 2017 Jan 19;8(1):e2560. Cell Death Dis. 2022 Feb 4;13(2):118. Cell Death Dis. 2023 Mar 28;14(3):219. Cell Mol Immunol. 2020 Mar;17(3):283-299. Cell Physiol Biochem. 2018;46(3):890-906. Cell Signal. 2020 Feb;66:109488. Cell Tissue Res. 2020 Jun;380(3):469-486. Cell Transplant. 2022 Jan-Dec;31:9636897221129171. Cells. 2019 Jul 22;8(7):761. Cells. 2022 Jan 4;11(1):155. Chinese Journal of Tissue Engineering Research. 2014,18(45): 7327-7332. Drug Des Devel Ther. 2022 Jan 6;16:67-81. Exp Ther Med. July 19, 2021. Fertil Steril. 2020 May;113(5):1067-1079.e5. Int J Biol Sci. 2017 May 5;13(5):604-614. Int J Mol Sci. 2023 Aug 13, 24(16), 12740. Int J Nanomedicine. 2023 Jul 31;18:4329-4346. J Diabetes Complicat. 2020 Oct;34(10):107654. J Mater Chem B. 2018 Apr 7;6(13):1951-1964. J Oncol. 08 Oct 2021. J Steroid Biochem Mol Biol. 2021 Jun 3;105926. J Transl Med. 2023 Sep 5;21(1):593. Kaohsiung J Med Sci. 2021 Nov 6. Ludwig maxime clinic. University of Munich. 2019 Apr. Mol Med Rep. 2020 Oct;22(4):3201-3212. Nano Today. 2022, 47: 101689. Oncogene. 2019 Jun;38(25):5021-5037. Oncol Lett. 2018 Sep;16(3):3976-3982. Patent. US20200360478A1. PLoS One. 2021 Mar 1;16(3):e0247707. Research Square Preprint. 2021 Aug. Research Square Preprint. 2021 Sep. Research Square Preprint. 2022 Jul. Research Square Preprint. 2023 Oct 23. SSRN. 5 Feb 2022. Stem Cells Int. 2020 Jul 7;2020:1498315. Theranostics. 2021 Jan 1;11(6):2612-2633. Transl Stroke Res. 2021 Jun 25. Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19. Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb. [1]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55. [2]Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926. [3]Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183(5):3204-11. [4]Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616. [5]Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71(2-3):216-26.
Smiles	[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.N1(CCCNCCNCCCNCC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AMD3100 (octahydrochloride); JM3100 (octahydrochloride); SID791 (octahydrochloride)
Lieferbar
Product Description	Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
Molecular Weight	794.47
Clinical Information	Launched
Solubility	DMSO : 1 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O : 100 mg/mL (ultrasonic)
Isoform	CXCR4; CXCR7; HIV-1; HIV-2
Pathway	Anti-infection; GPCR/G Protein; Immunology/Inflammation
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50912-50mg-safety-datasheet.pdf